New AAV treament guidelines in UK recommend rituximab use
Updated treatment guidelines from the British Society for Rheumatology favor rituximab over cyclophosphamide for active, relapsing ANCA-associated vasculitis (AAV), and set a standard maintenance treatment period of about 2-4 years after the disease has entered remission, or is determined to be well controlled. These recommendations are part of…